World first trial of cannabis-based drug to treat aggressive brain cancer gets the go aheadPosted by On


Hundreds of cancer patients in the UK will be given a cannabis-based drug to treat their aggressive brain tumours as part of a world first trial, it was announced today.

The Brain Tumour Charity raised £400,000 to back the three-year study, which will supplement glioblastoma patients’ chemotherapy treatment with Sativex — an oral spray containing cannabinoids.

Experts at the University of Leeds will look at whether the addition of the drug extends life for people diagnosed with the cancer. 

The trial will begin recruiting 230 patients at 15 hospitals across the UK early next year. 

If the drug works, it could become the first addition to NHS treatment for glioblastoma in more than a decade.  

Professor Susan Short, chief trial investigator and an expert in clinical oncology and neuro-oncology at Leeds University, said cannabinoids have ‘well-described effects’ in the brain and the trial will determine whether they help treat the most common and aggressive form of brain cancer. 

Around 2,200 people are diagnosed with glioblastoma every year in England. Even after intensive treatment, almost all glioblastomas recur and the average survival is just 12 to 18 months after diagnosis.

The trial ¿ dubbed ARISTOCRAT ¿ will determine whether adding Sativex to chemotherapy extends the patients' lives, slows the progression of their disease or improves their quality of life. Sativex is sprayed into the mouth and contains cannabinoids THC and CBD. Pictured: medicinal cannabis

The trial — dubbed ARISTOCRAT — will determine whether adding Sativex to chemotherapy extends the patients’ lives, slows the progression of their disease or improves their quality of life. Sativex is sprayed into the mouth and contains cannabinoids THC and CBD. Pictured: medicinal…

Original Author Link click here to read complete story..

Hundreds of cancer patients in the UK will be given a cannabis-based drug to treat their aggressive brain tumours as part of a world first trial, it was announced today.

The Brain Tumour Charity raised £400,000 to back the three-year study, which will supplement glioblastoma patients’ chemotherapy treatment with Sativex — an oral spray containing cannabinoids.

Experts at the University of Leeds will look at whether the addition of the drug extends life for people diagnosed with the cancer. 

The trial will begin recruiting 230 patients at 15 hospitals across the UK early next year. 

If the drug works, it could become the first addition to NHS treatment for glioblastoma in more than a decade.  

Professor Susan Short, chief trial investigator and an expert in clinical oncology and neuro-oncology at Leeds University, said cannabinoids have ‘well-described effects’ in the brain and the trial will determine whether they help treat the most common and aggressive form of brain cancer. 

Around 2,200 people are diagnosed with glioblastoma every year in England. Even after intensive treatment, almost all glioblastomas recur and the average survival is just 12 to 18 months after diagnosis.

The trial ¿ dubbed ARISTOCRAT ¿ will determine whether adding Sativex to chemotherapy extends the patients' lives, slows the progression of their disease or improves their quality of life. Sativex is sprayed into the mouth and contains cannabinoids THC and CBD. Pictured: medicinal cannabis

The trial — dubbed ARISTOCRAT — will determine whether adding Sativex to chemotherapy extends the patients’ lives, slows the progression of their disease or improves their quality of life. Sativex is sprayed into the mouth and contains cannabinoids THC and CBD. Pictured: medicinal…



Source link

News

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.